Despite what you may read elsewhere on the Internet, the Gleevec patent is not coming to an end soon in the US. While the original expiration date was May 28, 2013, Novartis was granted an extension to Jan 4, 2015. And as noted earlier, there are other issues as well. http://www.uspto.gov/patents/resources/terms/156.jsp
On Mar 11, 11:30 am, Vivi <[email protected]> wrote: > Unfortunately, the U.S. Food and Drug Administration is making it extremely > difficult for bio-similar generic drugs to be produced and marketed in the > U.S. I'm not familiar with the regulations in Canada but it's possible we > won't see a generic of Gleevec all that soon in the U.S. -- -- [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/CMLHope --- You received this message because you are subscribed to the Google Groups "CMLHope" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. For more options, visit https://groups.google.com/groups/opt_out.
